文献速递腹部技术与安全USCTMR

全氟丁烷增强超声联合常规B型超声用于肝细胞癌监测:多中心诊断试验(SCAN)

Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN).
PubMed 文献 · Radiology · 2019-07-09

这项前瞻性多中心单臂诊断试验在524例以乙肝相关肝硬化为主的人群中,比较常规B型超声单独与联合全氟丁烷增强超声监测肝细胞癌的效果;联合方案使假转诊率显著降低(差值-3.2%,95%CI -5.0%至-1.4%,P<.001),但早期肝细胞癌检出率未显著提高(差值0.4%,95%CI -0.3%至1.1%,P=.16)。

要点

  • 联合全氟丁烷增强超声使假转诊率显著降低,差值-3.2%(95%CI -5.0%至-1.4%,P<.001)。
  • 早期肝细胞癌检出率未显著提高,差值0.4%(95%CI -0.3%至1.1%,P=.16)。
  • 研究人群以乙肝相关肝硬化为主,493例(94.1%)为乙肝病毒感染相关肝硬化。

核心结论

  • 在乙肝病毒占优势的人群中,常规B型超声联合全氟丁烷增强超声可降低假转诊率,但未显著提高早期肝细胞癌检出率。

研究设计与样本

  • 前瞻性多中心单臂诊断试验,采用个体内比较设计,于五家转诊医院开展,2014年10月至2016年8月纳入因病毒性肝炎相关肝硬化接受超声监测的524例参与者(平均年龄54岁±9)。
  • 操作放射科医师在完成B型超声后、全氟丁烷增强超声前录入B型超声结果,随后完成全氟丁烷增强超声(Kupffer期,联合或不联合血管期)并记录结果。
  • 肝细胞癌诊断经病理分析或动态增强CT/钆塞酸二钠增强MRI影像学确认。
  • 主要终点为早期肝细胞癌(巴塞罗那临床肝癌分期0期或A期)检出率与假转诊率,按参与者逐一比较,采用McNemar检验。

诊断标准与关键数值

  • 早期肝细胞癌检出率:联合全氟丁烷增强超声较常规B型超声差值0.4%(95%CI -0.3%至1.1%),P=.16,差异未达统计学显著。
  • 假转诊率:联合全氟丁烷增强超声较常规B型超声差值-3.2%(95%CI -5.0%至-1.4%),P<.001,显著降低。
  • 早期肝细胞癌按巴塞罗那临床肝癌分期系统0期或A期定义,肝细胞癌存在经病理分析或动态增强CT/钆塞酸二钠增强MRI确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background US has served as a standard surveillance tool for hepatocellular carcinoma (HCC); however, the detection rate and false referral rate with this modality are suboptimal. Purpose To evaluate the added value of perfluorobutane-enhanced US when combined with conventional B-mode US as an HCC surveillance tool in participants with liver cirrhosis. Materials and Methods This prospective multi-institution diagnostic trial (https://ClinicalTrials.gov, NCT02188901) used an intraindividual comparison design in a single arm of study participants and was conducted at five referral hospitals. Eligible participants who had liver cirrhosis related to viral hepatitis and were undergoing US for HCC surveillance were enrolled from October 2014 to August 2016. Immediately after completion of B-mode US but before performance of perfluorobutane-enhanced US, operating radiologists entered the results of B-mode US. After completion of subsequent perfluorobutane-enhanced US (Kupffer phase with or without vascular-phase US), the radiologists recorded the results. The presence of HCC was confirmed either with pathologic analysis or radiologically by using dynamic contrast material-enhanced CT or gadoxetic acid-enhanced MRI. The primary end points were the detection rate of early-stage HCC (Barcelona Clinic Liver Cancer staging system stage 0 or A) and false referral rate. The primary end points were compared in a per-participant manner by using the McNemar test. Results A total of 524 participants (mean age, 54 years ± 9 [standard deviation]) were included. Of these, 493 (94.1%) had liver cirrhosis related to the hepatitis B virus. Ten HCCs were confirmed in eight participants. The detection rate of early-stage HCC was not significantly improved by adding perfluorobutane-enhanced US to conventional B-mode US (difference, 0.4% [95% confidence interval: -0.3%, 1.1%]; P = .16). The false referral rate was significantly reduced (difference, -3.2% [95% confidence interval: -5.0%, -1.4%]; P < .001). Conclusion The addition of perfluorobutane-enhanced US to conventional B-mode US reduced the false referral rate without a significant improvement in the detection rate of early-stage hepatocellular carcinoma for surveillance in a population in which the hepatitis B virus predominated. © RSNA, 2019 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Park JH, Park MS, Lee SJ, et al. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology. 2019. PMID: 31287387. doi:10.1148/radiol.2019190183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。